CAMBRIDGE, Mass., Feb. 6, 2026 /PRNewswire/ — Insilico Medicine (“Insilico”)  (3696.HK),  a clinical-stage biotechnology company powered by generative artificialCAMBRIDGE, Mass., Feb. 6, 2026 /PRNewswire/ — Insilico Medicine (“Insilico”)  (3696.HK),  a clinical-stage biotechnology company powered by generative artificial

Insilico Medicine Appoints Halle Zhang, PhD (Med), as Vice President, Clinical Development – Oncology

2026/02/06 21:31
5 min read

CAMBRIDGE, Mass., Feb. 6, 2026 /PRNewswire/ — Insilico Medicine (“Insilico”)  (3696.HK),  a clinical-stage biotechnology company powered by generative artificial intelligence (AI), today announced the appointment of Halle Zhang, PhD (Med), as Vice President, Clinical Development – Oncology. Dr. Zhang will report to Feng Ren, Co-Chief Executive Officer and Chief Scientific Officer of Insilico Medicine, and will be based in the company’s Cambridge, Massachusetts office.

In this role, Dr. Zhang will lead the global clinical development strategy and execution for Insilico’s oncology portfolio, guiding both early- and late-stage programs across multiple tumor types. She will also contribute to broader portfolio planning and the company’s growth strategy, partnering closely with discovery, translational, biomarker, regulatory, and clinical operations teams to accelerate development timelines and deliver differentiated, patient-centered therapies.

Dr. Zhang is a strategic leader in oncology clinical development with more than 20 years of experience spanning academia, biotechnology, and the pharmaceutical industry. Most recently, she served as Global Clinical Development Program Leader for late-stage oncology and Global Program Leader for early oncology at Bristol Myers Squibb, where she was accountable for global development strategy and execution across multiple solid tumor indications, including lung, breast, melanoma, gastric, colorectal, bladder, and head and neck cancers. Her experience spans diverse therapeutic modalities, including immuno-oncology–based approaches, targeted small-molecule therapies, and antibody–drug conjugates (ADCs), leading programs from first-in-human studies through registrational trials.

She worked closely with global regulatory authorities to shape development strategies, optimize study design, and support regulatory submissions, while integrating translational science and biomarker strategies into clinical plans. Over the course of her career, she has built and scaled high-performing clinical development organizations and is recognized for fostering a culture of scientific rigor, accountability, and collaboration.

Earlier, Dr. Zhang held senior clinical development leadership roles at Infinity Pharmaceuticals and BioMed Valley Discoveries and began her career in academic research and clinical operations at Harvard Medical School, where she led NIH-sponsored clinical trials. She holds a PhD in Medicine and an MSc in Immunology and Microbiology from University of Birmingham, and a BSc in Nursing from University of Portsmouth.

“Halle brings exceptional scientific depth, strategic judgment, and operational excellence to Insilico’s oncology programs,” said Alex Zhavoronkov, PhD, Founder and CEO of Insilico Medicine. “Her proven leadership across global oncology development will be instrumental as we continue to expand our AI-driven pipeline and translate innovative science into meaningful clinical outcomes for patients.”

“I am excited to join Insilico Medicine at such an important stage of growth,” said Dr. Zhang. “Insilico’s unique AI-driven platform, combined with a bold, science-first culture, creates a powerful opportunity to rethink how oncology medicines are discovered and developed. I look forward to partnering with this talented team to advance therapies that address significant unmet needs for patients.”

Over the past year, Insilico Medicine’s oncology pipelines have been moving forward with high efficiency. Several innovative pipelines designed and optimized with the help of Chemistry42 have progressed to Phase I clinical trials. In January 2025, ISM6331, a pan-TEAD inhibitor with an innovative structure, was announced to have completed first patient dosing in a global, multicenter Phase I clinical trial for the treatment of mesothelioma and other solid tumors. In June 2025, ISM3412, a potential “best-in-class” inhibitor targeting MAT2A, was announced to have completed first patient dosing in patients with locally advanced and metastatic solid tumors, aiming to evaluate safety, tolerability, PK/PD characteristics, and preliminary efficacy.

In addition to advancing its internal pipeline, Insilico Medicine and its global partners have achieved multiple milestones across collaborative oncology programs. The company entered a multi-program discovery and development collaboration with Servier valued at up to USD $888 million to leverage Insilico’s AI platform to generate first-in-class small-molecule cancer therapies. Under its collaboration totaling up to USD $550 million with Menarini Group, Insilico received a USD $3 million development and regulatory milestone payment in July 2025, followed by a USD $5 million milestone upon dosing the first patient in the Phase I clinical trial of MEN2501 (ISM9682), a highly differentiated KIF18A small-molecule inhibitor.

Harnessing state-of-the-art AI and automation technologies, Insilico has significantly improved the efficiency of preclinical drug development. While traditional early-stage drug discovery typically requires 3 to 6 years, from 2021 to 2024 Insilico nominated 20 preclinical candidates, achieving an average turnaround – from project initiation to preclinical candidate (PCC) nomination – of just 12 to 18 months per program, with only 60 to 200 molecules synthesized and tested in each program.

About Insilico Medicine

Insilico Medicine, a leading and global AI-driven biotech company, utilizes its proprietary Pharma.AI platform and cutting-stage automated laboratory to accelerate drug discovery and advance innovations in life sciences research. By integrating AI and automation technologies and deep in-house drug discovery capabilities, Insilico is delivering innovative drug solutions for unmet needs including fibrosis, oncology, immunology, pain, and obesity and metabolic disorders. Additionally, Insilico extends the reach of Pharma.AI across diverse industries, such as advanced materials, agriculture, nutritional products and veterinary medicine. For more information, please visit www.insilico.com.

Cision View original content:https://www.prnewswire.com/news-releases/insilico-medicine-appoints-halle-zhang-phd-med-as-vice-president-clinical-development–oncology-302681141.html

SOURCE Insilico Medicine

Market Opportunity
MASS Logo
MASS Price(MASS)
$0.0003062
$0.0003062$0.0003062
-30.31%
USD
MASS (MASS) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.
Tags:

You May Also Like

Which Altcoins Stand to Gain from the SEC’s New ETF Listing Standards?

Which Altcoins Stand to Gain from the SEC’s New ETF Listing Standards?

On Wednesday, the US SEC (Securities and Exchange Commission) took a landmark step in crypto regulation, approving generic listing standards for spot crypto ETFs (exchange-traded funds). This new framework eliminates the case-by-case 19b-4 approval process, streamlining the path for multiple digital asset ETFs to enter the market in the coming weeks. Grayscale’s Multi-Crypto Milestone Grayscale secured a first-mover advantage as its Digital Large Cap Fund (GDLC) received approval under the new listing standards. Products that will be traded under the ticker GDLC include Bitcoin, Ethereum, XRP, Solana, and Cardano. “Grayscale Digital Large Cap Fund $GDLC was just approved for trading along with the Generic Listing Standards. The Grayscale team is working expeditiously to bring the FIRST multi-crypto asset ETP to market with Bitcoin, Ethereum, XRP, Solana, and Cardano,” wrote Grayscale CEO Peter Mintzberg. The approval marks the US’s first diversified, multi-crypto ETP, signaling a shift toward broader portfolio products rather than single-asset ETFs. Bloomberg’s Eric Balchunas explained that around 12–15 cryptocurrencies now qualify for spot ETF consideration. However, this is contingent on the altcoins having established futures trading on Coinbase Derivatives for at least six months. This includes well-known altcoins like Dogecoin (DOGE), Litecoin (LTC), and Chainlink (LINK), alongside the majors already included in Grayscale’s GDLC. Altcoins in the Spotlight Amid New Era of ETF Eligibility Several assets have already met the key condition, regulated futures trading on Coinbase. For example, Solana futures launched in February 2024, making the token eligible as of August 19. “The SEC approved generic ETF listing standards. Assets with a regulated futures contract trading for 6 months qualify for a spot ETF. Solana met this criterion on Aug 19, 6 months after SOL futures launched on Coinbase Derivatives,” SolanaFloor indicated. Crypto investors and communities also identified which tokens stand to gain. Chainlink community liaison Zach Rynes highlighted that LINK could soon see its own ETF. He noted that both Bitwise and Grayscale have already filed applications. Meanwhile, the Litecoin Foundation indicated that the new standards provide the regulatory framework for LTC to be listed on US exchanges. Hedera is also in the spotlight, with digital asset investor Mark anticipating an HBAR ETF. Market observers see the decision as a potential turning point for broader adoption, bringing the much-needed clarity and accessibility for investors. At the same time, it boosts confidence in the market’s maturity. The general sentiment is that with the SEC’s approval, the next phase of crypto ETFs is no longer a question of ‘if,’ but ‘when.’ The shift to generic listing standards could expand the US-listed digital asset ETFs roster beyond Bitcoin and Ethereum. Such a move would usher in new investment vehicles covering a dozen or more altcoins. This represents the clearest path yet toward mainstream, regulated access to diversified crypto exposure. More importantly, it comes without the friction of direct custody. “We’re gonna be off to the races in a matter of weeks,” ETF analyst James Seyffart quipped.
Share
Coinstats2025/09/18 12:57
Zhongchi Chefu acquired $1.87 billion worth of digital assets from a crypto giant for $1.1 billion.

Zhongchi Chefu acquired $1.87 billion worth of digital assets from a crypto giant for $1.1 billion.

PANews reported on February 10th that Autozi Internet Technology (Global) Ltd. (AZI), a US-listed Chinese company, has successfully acquired approximately $1.87
Share
PANews2026/02/10 20:36
XRP news: Ripple expands RLUSD stablecoin use in UAE via Zand Bank

XRP news: Ripple expands RLUSD stablecoin use in UAE via Zand Bank

Ripple has expanded the reach of its RLUSD stablecoin in the Middle East through a new strategic partnership with UAE-based digital bank Zand, a move that could
Share
Crypto.news2026/02/10 20:08